Hodgkin lymphoma - management
Hodgkin · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
A curable lymphoma characterised by Reed-Sternberg cells, typically presenting with painless lymphadenopathy and sometimes B symptoms. Stage-adapted, response-adapted chemotherapy (with or without radiotherapy) achieves high cure rates.
Red flags
- SVC obstruction from mediastinal mass
- Airway compromise
- Spinal cord compression
- Rapidly progressive bulky disease
- Severe B symptoms with deterioration
Assessment
Differential diagnosis
- Non-Hodgkin lymphoma
- Reactive lymphadenopathy / infection
- Sarcoidosis
- Metastatic carcinoma
- Tuberculosis
- Nodular lymphocyte-predominant Hodgkin lymphoma
Investigations
- Excisional lymph node biopsy (core often insufficient)
- FBC, ESR, LDH, LFTs, renal function
- HIV, hepatitis B/C serology
- PET-CT for staging and interim response
- Bone marrow (often replaced by PET)
- Echocardiogram and lung function before anthracycline/bleomycin
Management
- Confirm diagnosis by excisional biopsy with expert haematopathology
- Stage with PET-CT (Ann Arbor / Lugano) and identify B symptoms and bulk
- Assess cardiac and pulmonary fitness and fertility preservation before therapy
- Treat early-stage favourable disease with short combined chemotherapy +/- involved-site radiotherapy
- Treat advanced-stage disease with multi-agent chemotherapy (ABVD or escalated regimens / brentuximab-AVD)
- Use interim PET to adapt therapy - de-escalate or intensify by response
- Omit or modify bleomycin based on PET response and lung toxicity risk
- Manage relapsed/refractory disease with salvage chemotherapy and autologous transplant
- Use brentuximab vedotin and checkpoint inhibitors (nivolumab/pembrolizumab) in relapse
- Provide survivorship care for late cardiac, pulmonary and second-malignancy risks
Drugs & doses
ABVD: doxorubicin 25 mg/m2 + bleomycin 10 units/m2 + vinblastine 6 mg/m2 + dacarbazine 375 mg/m2 IV days 1 & 15 per cycle
Brentuximab vedotin-AVD for advanced disease (replaces bleomycin)
Pembrolizumab or nivolumab for relapsed/refractory disease
Antiemetics and growth factor support as needed
Disposition
Haematology/oncology outpatient-led therapy; urgent admission for mass-effect emergencies; long-term survivorship follow-up.
Complications & pitfalls
- Bleomycin lung toxicity
- Anthracycline cardiotoxicity
- Infertility
- Secondary malignancies (breast, lung, leukaemia)
- Relapse
Exam pearls
- Hodgkin lymphoma is highly curable even at advanced stage
- Interim PET enables response-adapted therapy to limit toxicity
- Excisional biopsy is preferred for diagnosis
- Discuss fertility preservation before starting treatment
- Long-term survivorship surveillance for cardiac disease and second cancers is essential
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.